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Abstract
Background: The EuroQol-5 Dimension (EQ-5D), developed in 1990, is a most widely used generic tool to measure the
health-related quality of life (HRQoL) and considered suitable for patients with asthma. In 2009, the EuroQol Group developed
a new EQ-5D version to overcome limitations related to its consistently reported high ceiling effect. To enhance the sensitivity
for assessing the HRQoL in further patient populations, the number of responses of EQ-5D was increased from 3 to 5 levels
(EQ-5D-5L). Moreover, the availability of well-defined requirements for its Web-based administration allows EQ-5D-5L use to
monitor the HRQoL in electronic health (eHealth) programs. No study has evaluated the metric properties of the new EQ-5D-5L
in patients with asthma yet.
Objective: This study aims to examine the distribution, construct validity, and reliability of the new EQ-5D-5L questionnaire
administered online to adults with asthma.
Methods: We evaluated patients with asthma (age: 18-40 years) from a primary care setting in France and England, who
self-completed the EQ-5D-5L questionnaire online. The inclusion criteria were persistent asthma defined as >6 months of prescribed
inhaled corticosteroids and long-acting beta-agonists or inhaled corticosteroids alone during the 12 months prior to inclusion.
The EQ-5D index was obtained by applying the English preference value set for the new EQ-5D-5L and the French 3L-5L
crosswalk value set. Both value sets produced single preference-based indices ranging from 1 (best health state) to negative values
(health states valued as worse than death), where 0=death, allowing the calculation of quality-adjusted life years. Responses to
dimensions and index distribution, including ceiling and floor effects, were examined. The construct validity was assessed by
comparing the means of known groups by analyses of variance and calculation of effect sizes.
Results: Of 312 patients answering the baseline Web-based survey, 290 completed the EQ-5D-5L (93%). The floor effect was
null, and the ceiling effect was 26.5% (74/279). The mean EQ-5D-5L index was 0.88 (SD 0.14) with the English value set and
0.83 (SD 0.19) with the French 3L-5L crosswalk value set. In both indices, large effect sizes were observed for known groups
defined by the Asthma Control Questionnaire (1.06 and 1.04, P<.001). Differences between extreme groups defined by chronic
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conditions (P=.002 and P=.003 for the English value set and French 3L-5L crosswalk value set, respectively), short-acting
beta-agonists (SABAs) canisters in the last 12 months (P=.02 and P=.03), or SABA use during the previous 4 weeks (P=.03 and
P=.01) were of moderate magnitude with effect sizes around 0.5.
Conclusions: The new EQ-5D-5L questionnaire has an acceptable ceiling effect, a good construct validity based on the
discriminant ability for distinguishing among health-related known groups, and high reliability, supporting its adequacy for
assessing the HRQoL in patients with asthma. EQ-5D-5L completion by most Web-based respondents supports the feasibility of
this administration form.
(J Med Internet Res 2019;21(1):e10178)   doi:10.2196/10178
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Introduction
The impact of asthma on the patients’ health has been
traditionally assessed by either clinical markers or functional
tests [1]. Patient-reported outcome measures, such as symptom
control or health-related quality of life (HRQoL), have shown
to be useful for clinical management, understanding disease
impact on the patients’ functional status and well-being, and
cost-effectiveness analyses [2]. Hence, international guidelines
for asthma diagnosis and treatment have emphasized that
treatment goals should include the improvement of the patients’
HRQoL [3].
In asthma, disease-specific HRQoL measures have been more
widely used than generic ones, as they could be more sensitive.
Adding generic HRQoL domains important to patients with
asthma has been proposed [4] because asthma-specific HRQoL
instruments measure similar contents to those covered by asthma
control questionnaires [5,6] such as symptoms and activity
limitations. Generic HRQoL instruments are broad measures
that can be applied in patients with various conditions and the
general population. The EuroQol-5 Dimensions (EQ-5D),
developed in 1990 by the EuroQol Group, is one of the most
widely used generic tools owing to its low respondent burden,
good psychometric properties, and econometric development
[7-9]. In addition, the availability of well-defined requirements
for its Web-based administration by multiple devices, such as
personal computer, tablet, or smartphones, makes this instrument
adequate for monitoring the HRQoL in eHealth programs [10].
The EQ-5D was considered a suitable generic measure in a
systematic review [11] of patient-reported outcome measures
for patients with asthma. This health status measure allows the
calculation of quality-adjusted life years (QALYs) when society
preferences are applied and cost-utility analysis in economic
evaluations [12-14]. However, to the best of our knowledge,
only 3 studies have evaluated its psychometric properties in
patients with asthma [15-17]. Garratt et al [16] showed a
moderate EQ-5D association with asthma-specific HRQoL
instruments and external variables such as smoking status and
education level. Oga et al [15] and McTaggart-Cowan et al [17]
reported a high ceiling effect (59% and 50% of the sample with
the maximum score, respectively) questioning the usefulness
of the EQ-5D in asthmatic patients. In fact, limitations related
to the high ceiling effect have also been consistently reported
for the EQ-5D in other chronic conditions such as chronic
obstructive pulmonary disease [18], osteoarthritis [18], diabetes
[19], and coronary heart disease [20].
The traditional EQ-5D descriptive system, composed of 5
dimensions with 3 levels of severity, defines 243 distinct health
states resulting from all the possible combinations (ie, 35); this
is a low number compared with other generic preference-based
instruments such as the Health Utilities Index [21] or the SF-6D
[22] with 972,000 and 18,000 possible combinations,
respectively. To improve its sensitivity, the EuroQol Group
developed a new EQ-5D version, by increasing the number of
responses from 3 to 5 levels, known as EQ-5D-5L, with 3125
health states (ie, 55) [23].
The new EQ-5D-5L has already been tested in some
disease-specific samples, such as patients with cancer [24,25]
and with hepatitis [26], showing a better discrimination
capability and lower ceiling effects than the traditional 3-level
version (11% vs 17% [24], 9.7% vs 16.8% [25], and 21.6% vs
38.3% [26]). However, to date, no study has evaluated metric
properties of the new 5-level EQ-5D in patients with asthma.
Hence, this study aims to examine the distribution, construct
validity, and reliability of the new EQ-5D-5L administered
online to adults with asthma.
Methods
Setting and Study Population
In this study, we analyzed baseline data of adults (age: 18-40
years) enrolled in the ASTRO-LAB cohort who completed the
EQ-5D-5L questionnaire. The ASTRO-LAB project is a
prospective longitudinal study of asthmatic patients designed
to provide new evidence regarding the safety of long-acting
beta-agonists (LABAs) in routine primary care in France and
the United Kingdom. Details of the study are described
elsewhere [27].
The inclusion criteria were as follows: persistent asthma and
age <40 years. Patients were considered to have persistent
asthma when they had >6 months of prescribed treatment with
inhaled corticosteroids (ICs) and LABAs or ICs alone during
the 12 months prior to inclusion. Persistent asthma requires
controller therapy on a regular basis, whereas intermittent
asthma can be treated with rescue medication as needed. The
ASTRO-LAB persistent asthma definition was based on a
minimal prescription duration level of antiasthmatic drugs
because this method is considered less biased than the
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practitioner’s classification of asthma, and it is frequently used
in database studies [28]. The ASTRO-LAB project’s age limit
was chosen to minimize the recruitment of patients with other
comorbid conditions frequent at older ages, most importantly
chronic obstructive pulmonary disease, often overlapped and
difficult to exclude without specific tests.
The exclusion criteria were as follows: chronic oral
corticosteroid use (≥15 consecutive days 3 months before
inclusion), history of omalizumab therapy, and any other
concomitant chronic respiratory disease (chronic obstructive
pulmonary disease, cystic fibrosis, pulmonary fibrosis,
bronchiectasis, or tuberculosis). Owing to ASTRO-LAB’s main
focus being LABAs safety, the abovementioned criteria based
on the administration of other medications aimed at avoiding
confounding with their adverse effects, implying that most
patients with severe persistent asthma were excluded.
The ASTRO-LAB study has been approved by the Ethics and
Regulatory Boards in France and the United Kingdom and was
conducted in accordance with the Declaration of the World
Medical Association. In France, approval was obtained from
CCTIRS (Comité consultatif sur le traitement de l’information
en matière de recherche dans le domaine dela santé) on
November 21, 2012 (Dossier N°12702), and the authorization
from Commission Nationale d’Informatique et Liberté was
obtained in May 17, 2013 (DR-2013-264). In the United
Kingdom, according to the UK Research Governance
Framework, the study was submitted to The West London
Research Ethics Committee (REC), and the final approval was
obtained on April 15, 2013 (REC Reference 12/LO/20139).
Following the UK regulatory process, the ASTRO-LAB
consortium submitted the protocol to the National Institute for
Health Research Clinical Research Network (NIHR CRN) to
launch the review by Primary Care Trust local sites. The first
local approval was granted by the West London Primary Care
Consortium on May 22, 2013. Informed consent was obtained
from all participants prior to inclusion.
Measurement Instruments
Clinical data were extracted from medical records, and
patient-reported information was obtained by the following 2
administration modes: patient-completed Web-based survey
and telephone interviews with patients performed by trained
interviewers. The EQ-5D-5L was only administered in the
Web-based survey.
Clinical Data
Information on age, gender, body mass index, comorbidity, and
treatment prescribed was obtained; in France, general
practitioners completed a Web-based survey at patient inclusion,
while in the United Kingdom, this information was directly
extracted from medical records. The history of 4 associated
pathologies (allergic rhinitis, nasal polyps, anxiety or depression,
and gastroesophageal reflux), was registered and transformed
into a count variable. The total number of short-acting
beta-agonist (SABA) canisters prescribed in the 12 months prior
to inclusion was transformed into a variable of 3 categories—0,
1-4, and ≥5 canisters.
Patient-Completed Web-Based Survey
Patients received instructions during the recruitment contact to
self-complete a Web-based survey, which included the
EQ-5D-5L to measure the HRQoL and sociodemographic data,
such as their highest level of education and current work
situation, among others.
The EQ-5D-5L is a brief, multiattribute, generic, health status
measure composed of 5 questions with Likert response options
(descriptive system) and a visual analog scale (EQ-VAS). The
latter asks patients to rate their own health from 0 to 100 (the
worst and best imaginable health, respectively). The descriptive
system covers 5 dimensions of health (mobility, self-care, usual
activities, pain or discomfort, and anxiety or depression) with
5 levels of severity in each dimension (no problems, slight
problems, moderate problems, severe problems, and unable to
perform or extreme problems).
Preference value sets used to obtain the index of the EQ-5D-5L
were the 3L-5L crosswalk from the French 3L version [29], and
the new EQ-5D-5L value set from England [30]. In both cases,
single preference-based indices were produced ranging from 1
(the best health state) to negative values (health states valued
as worse than death), where 0=death. The minimal important
difference for the EQ-5D index was estimated as 0.07 [31].
Telephone Interviews
The telephonic interviews were computer-assisted to standardize
the process. Trained interviewers administered questions to
patients about their asthma control and treatment use, among
others. Asthma control is defined as the extent to which the
manifestations of asthma can be observed in a patient, or have
been reduced or removed by treatment [32,33]; it reflects the
suitability of the asthma treatment.
The Asthma Control Questionnaire (ACQ) is composed of 7
items—the top scoring 5 symptoms, FEV1% predicted, and
daily rescue bronchodilator use. A shorter version called
ACQ-symptoms only [34] was developed to use when it is not
feasible to collect data about the last 2 items, as in
ASTRO-LAB. It assesses the frequency of the 5 asthma
symptoms during the previous week on a 7-point Likert scale
(0=no impairment, 6=maximum impairment). The overall score,
calculated as the mean of item responses, ranges from 0 to 6.
A score <0.75 was defined as well-controlled asthma; 0.75-1.5
as intermediate control; and >1.5 as not well-controlled asthma
[35]. The results generated by the short versions have shown to
be very similar to those of the complete ACQ, as well as its
measurement properties (reliability, responsiveness, internal
consistency, construct validity, and interpretability) [34].
The following question was asked to patients with SABA
therapy prescription: “How often have you usually taken your
‘reliever medication’ (brand name) in the past 4 weeks? Every
day; almost every day; once or twice every week; less than once
a week; or I don’t know.”
Analytic Strategy
Sample characteristics were described by calculating
percentages, or mean (SD) values, according to the variable
type (detailed in tables and figures). To examine the nonresponse
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bias, subjects who completed the Web-based survey were
compared with those who had not completed this survey by a t
test and chi-square test.
We calculated the percentages of responses to each EQ-5D-5L
dimension. To examine the distribution of the EQ-5D index,
we calculated statistics of central tendency, dispersion,
asymmetry, and tail extremity, as well as the proportion and
95% CI of the individuals in the best possible (ceiling) and the
worst possible (floor) health states [36]. To assess the reliability
based on the internal consistency, the Cronbach alpha coefficient
was estimated.
The construct validity examines whether the instrument
adequately assesses the concept that it intends to measure [37],
in this case the HRQoL. The strategy to evaluate the construct
validity based on known groups consists of testing the ability
of the instrument to discriminate among groups previously
hypothesized as differing in the concept measured. The
following variables were chosen to test the instrument’s capacity
to discriminate, as differences have been consistently shown in
the HRQoL among groups defined by them [1,15,38,39]—the
number of chronic conditions (as an indicator of general health),
number of SABA canisters prescribed in the previous year,
frequency of SABA inhaler use during the previous 4 weeks,
and ACQ scores (as 3 indicators of asthma control). We
hypothesized that asthma patients with worse general health or
less asthma control report worse HRQoL.
To evaluate the discriminative capacity of the EQ-5D index and
EQ-VAS among the known groups mentioned above, mean
scores were compared using one-way analysis of variance and
the Tukey studentized range (honestly significant difference)
test for post-hoc comparisons; alpha was set at.05. To assess
the magnitude of the differences Cohen effect sizes were
calculated. General guidelines define an effect size of 0.2 as
small, 0.5 as moderate, and 0.8 as large [40]. All analyses were
conducted using the statistical package SPSS (IBM SPSS
Statistics for Windows, Version 23.0, IBM Corp)
Results
Study Sample
Of 581 subjects with asthma aged 18-40 years composing the
ASTRO-LAB cohort, 312 filled in the baseline Web-based
survey (Web-based participation rate, 53.7%), but 22 of these
did not complete the EQ-5D-5L (questionnaire nonresponse
rate, 7.0%). Of 290 who fulfilled the EQ-5D-5L, 11 were
excluded because they had missing data on all the variables
selected to define known groups; hence, 279 patients were
finally included in this analysis. Table 1 shows patients’ baseline
characteristics, comparing the included subjects with excluded
ones (mainly because of not responding to the Web-based
survey). Most of the included subjects were from France and
had been treated with fixed-dose combinations of LABA and
IC. More than half of them had completed a bachelor degree
(66.9%, 184/275), and 72.6% (201/277) were employed in their
usual jobs. These 2 variables were only available for patients
included in the analysis, as they were recorded in the Web-based
questionnaire. Nonrespondents were younger (aged 29.8 vs 31.0
years, P=.03), and presented higher ACQ mean scores (worse
control) in comparison to respondents but did not differ in body
mass index, treatment, number of other chronic conditions,
SABA canisters prescribed last year, and frequency of SABA
used in the previous 4 weeks.
5-Level EuroQoL-5 Dimension Version Distribution
Figure 1 shows the percentages of responses to each EQ-5D-5L
dimension. Most subjects reported “no problems” in mobility
(81.0%, 226/279) and self-care (98.2%, 274/279) dimensions,
while only around half of the subjects endorsed this category
in pain or discomfort (45.5%, 127/279) and anxiety or
depression (48.0%, 134/279) dimensions. The “extreme
problems” category was endorsed by 1 subject for pain and 7
for anxiety or depression.
Table 2 shows the distribution characteristics of EQ-5D-5L
indices. In our sample, the EQ-5D-5L index constructed with
the English value set ranged from 0.16 to 1 and from –0.074 to
1 when constructed with the French 3L-5L crosswalk value set.
The mean was 0.88 (SD 0.14) for the English index and 0.83
(SD 0.19) for the French one. The Kurtosis statistics of 5.62
and 3.26, with skewness of –2.06 and –1.63, indicated that the
asymmetry to the right part of the distribution and the tail
extremity were greater in the index constructed with the English
EQ-5D-5L value set. The floor effect was null, and the ceiling
effect was 26.5% (74/279). Cronbach alpha coefficient was .69,
achieving the recommended standard [36,37].
5-level EuroQoL-5 Dimension Version Construct
Validity
Table 3 presents results on the construct validity of the
EQ-5D-5L based on known groups. Both EQ-5D-5L indices
showed statistically significant different means for all known
groups evaluated, while EQ-VAS only showed statistically
significant differences among groups defined by ACQ scores.
The mean EQ-5D-5L index for asthmatic patients decreased
significantly with an increase in the number of other chronic
conditions from 0.91 to 0.82 with the English value set and from
0.86 to 0.75 with the French 3L-5L crosswalk. The effect size
between patients with none and those with ≥2 other chronic
conditions were 0.62 and 0.60 (moderate) with EQ-5D-5L
indices. In addition, effect sizes were moderate between extreme
groups defined by SABA canisters prescribed in the previous
year (0.58 and 0.46), and by the SABA frequency during the
last 4 weeks (both 0.5). Finally, among groups defined by ACQ
scores, the effect size between well-controlled and
intermediately controlled asthma was moderate (0.44 and 0.47)
and large between well- and not well-controlled asthma (1.06
and 1.04).
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Table 1. The characteristics of included and excluded subjects.
P valueExcluded patients (n=302)Included patients (n=279)Characteristics
.0329.8 (6.7)31.0 (6.7)Age (years), mean (SD)
.1085 (28.1)62 (22.2)<25, n (%)
133 (44.0)119 (42.7)25-34, n (%)
84 (27.8)98 (35.1)≥35, n (%)
.47Gender, n (%)
128 (42.4)110 (39.4)Male
174 (57.6)169 (60.6)Female
.01Country
264 (87.7)222 (79.6)France, n (%)
37 (12.3)57 (20.4)United Kingdom, n (%)
10Missing (n)
.7925.4 (5.8)25.2 (6.2)Body mass index (kg/m2), mean (SD)
107127Missing (n)
.18Treatment with, n (%)
9 (3.0)11 (3.9)LABAa
60 (19.9)71 (25.4)ICsb
33 (10.9)37 (13.3)LABA+ICs in separate inhalers
200 (66.2)160 (57.3)Fixed LABA and ICs combination
.51Other chronic conditions
80 (39.2)66 (41.5)0 conditions, n (%)
91 (44.6)62 (39.0)1 condition, n (%)
33 (16.2)31 (19.5)≥2 conditions, n (%)
98120Missing (n)
.75Number of SABAc canisters prescribed (last year)
133 (50.2)119 (53.6)0 canisters, n (%)
100 (37.7)78 (35.1)1-4 canisters, n (%)
32 (12.1)25 (11.3)≥5 canisters, n (%)
—d57Missing (n)
.63Frequency of SABA use reported by patient (last 4 weeks)
171 (65.5)166 (61.9)Less than once a week, n (%)
60 (23.0)71 (26.5)Once or twice every week, n (%)
30 (11.5)31 (11.6)Almost every day or every day, n (%)
4111Missing (n)
<.0011.35 (1.01)1.01 (0.92)Asthma Control Questionnaire, mean (SD)
<.00189 (34.1)119 (44.6)Well-controlled (<0.75), n (%)
63 (24.1)82 (30.7)Intermediate (0.75-1.5), n (%)
109 (41.8)66 (24.7)Not well-controlled (>1.5), n (%)
4112Missing (n)
Not calculatedHighest education
—13 (4.7)Secondary school or less, n (%)
—41 (14.9)Sixth form or college, n (%)
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P valueExcluded patients (n=302)Included patients (n=279)Characteristics
—184 (66.9)Bachelor degree, n (%)
—37 (13.5)Postgraduate, n (%)
—4Missing (n)
Not calculatedWork status
—201 (72.6)Employed at usual job, n (%)
—1 (0.4)On light duty or restricted work, n (%)
—4 (1.4)Paid leave or sick leave, n (%)
—23 (8.3)Unemployed because of other reason, n (%)
—35 (12.6)Student (school, college, university), n (%)
—7 (2.5)Keeping house or homemaker, n (%)
—0 (0.0)Retired, n (%)
—6 (2.2)On disability, n (%)
—2Missing (n)
aLABA: long-acting beta-agonist.
bIC: inhaled corticosteroid.
cSABA: short-acting beta-agonist.
dIndicates missing data.
Figure 1. The percentage of patients’ responses to each dimension.
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Table 2. The distribution of 5-level EuroQoL-5 dimension version indices (n=279). Cronbach alpha coefficient was .69.
EQ-5D-5L (French 3L-5L crosswalk value set)EQ-5D-5La (English value set)Statistics
–0.530 to 1–0.28097 to 1Theoretical range
–0.074 to 10.160 to 1Observed range
0.83 (0.19)0.88 (0.14)Mean (SD)
0.91 (0.71 to 1.00)0.92 (0.84 to 1.00)Median (interquartile range)
3.26 (0.29)5.62 (0.29)Kurtosis (SE)
–1.63 (0.15)–2.06 (0.15)Skewness (SE)
00Floor effect (%)
26.526.5Ceiling effect (%)
aEQ-5D-5L: EuroQol-5 Dimensions-5 Levels.
Table 3. The construct validity of 5-level EuroQoL-5 dimension version.
EuroQol visual analog scaleEQ-5D-5L index (French 3L-5L
crosswalk)
EQ-5D-5La index (English value
set)
Constructs
Effect size (95% CI)Mean (SD)Effect size (95% CI)Mean (SD)Effect size (95% CI)Mean (SD)
Other chronic conditions
Reference78.91 (14.85)Reference0.86 (0.14)Reference0.91 (0.11)0 chronic conditions
0.06 (–0.25 to 0.37)79.08 (13.23)0.05 (–0.26 to 0.36)0.85 (0.15)0.14 (–0.21 to 0.48)0.89 (0.10)1 chronic condition
0.37 (–0.04 to 0.79)72.94 (17.22)0.60 (0.18 to 1.02)0.75 (0.20)0.62 (0.18 to 1.06)0.82 (0.13)≥2 chronic conditions
—.12—.003b,c—d.002b,cP value
Number of SABAe canisters prescribed (last year)
Reference78.84 (12.90)Reference0.85 (0.15)Reference0.89 (0.11)0 canisters
0.21 (–0.06 to 0.47)76.64 (17.93)0.19 (–0.07 to 0.45)0.82 (0.19)0.11 (–0.18 to 0.39)0.87 (0.14)1-4 canisters
0.47 (0.07 to 0.88)72.00 (24.52)0.46 (0.05 to 0.86)0.76 (0.22)0.58 (0.14 to 1.01)0.81 (0.17)5 or more canisters
—.15—.03b—.02bP value
Frequency of SABA use reported by patient (last 4 weeks)
Reference71.45 (19.85)Reference0.74 (0.23)Reference0.82 (0.19)Less than once a week
0.07 (–0.19 to 0.32)78.08 (12.92)0.29 (0.03 to 0.55)0.81 (0.21)0.17 (–0.11 to 0.44)0.87 (0.15)Once or twice a week
0.37 (0.03 to 0.71)78.61 (16.26)0.50 (0.15 to 0.84)0.85 (0.16)0.50 (0.11 to 0.89)0.89 (0.12)Almost every day or every
day
—.07—.01b—.03bP value
Asthma Control Questionnaire
Reference81.65 (13.80)Reference0.91 (0.13)Reference0.93 (0.10)Well-controlled (<0.75)
0.15 (–0.11 to 0.40)79.18 (11.92)0.47 (0.22 to 0.73)0.81 (0.15)0.44 (0.15 to 0.72)0.87 (0.11)Intermediate (0.75-1.5)
0.79 (0.51 to 1.08)68.39 (20.23)1.04 (0.75 to 1.32)0.69 (0.24)1.06 (0.74 to 1.38)0.78 (0.19)Not well-controlled (>1.5)
—<.001b,c—<.001b,c,f—<.001b,c,fP value
aEuroQol-5 Dimensions-5 Levels.
bFirst category (reference) versus third category.
cSecond category versus third category.
dP value not necessary as the CI was calculated.
eSABA: short-acting beta-agonist.
fFirst category (reference) versus second category.
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Discussion
Principal Findings
To the best of our knowledge, this is the first study evaluating
metric properties of the new EQ-5D-5L in patients with asthma.
In this study, this generic preference-based instrument showed
adequate distribution and reliability, with 26.5% (74/279) of
patients reporting the best possible health state (ceiling effect).
In addition, it showed good construct validity, given its capacity
of discriminating among groups differing in the number of
chronic conditions and symptom control. The distribution of
the EQ-5D-5L index was less skewed than the previously
published one for the 3-level version owing to its lower ceiling
effect [15,17].
Comparison of Web-Based Participation Rate With
Prior Work
In this study, 53.7% (312/581) of participants completed the
Web-based baseline survey, and almost all of these completed
the EQ-5D-5L (92.9%, 290/312). The internet era has led to
implementing Web-based surveys to take advantage of the
known benefits such as completeness [41,42], low expenses
[43], and better data management. Nevertheless, there are still
some barriers to Web-based self-completion, which could
produce low response rates and selection bias. Although the
reported participation rate varied a lot across Web-based surveys
[41,44,45], the 53.7% in this study is similar to those reported
by other studies comparing different modes of data collection,
such as 64.2% and 53.3% participation rates reported by
Kongsved et al [41] and Hohwu et al [46] studies. Remarkably,
both studies showed a slightly better response rate with the
paper mode—73.2% versus 64.2% [41] and 56.2% versus 53.3%
[46]. In the ASTRO-LAB cohort, the high overall respondent
burden (participants were asked to respond to yearly Web-based
surveys, 4-monthly telephone interviews, and monthly short
message service text messages) could have affected the response
rate.
Comparison With Prior Studies Evaluating the
EuroQoL-5 Dimension Version in Patients With
Asthma
Despite being higher than the 15% [36] established for the
ceiling effect, 26.5% (74/279) of patients with mild-to-moderate
persistent asthma in the best possible health state in our sample
was considerably lower than that reported in prior studies using
the traditional EQ-5D-3L in paper-and-pencil administration
[15,17]. A ceiling effect of 59% was described in Japanese
patients with mild-to-severe asthma treated with ICs [15], and
50% in Canadian patients with mainly mild-to-moderate
self-reported asthma [17]. In addition, our findings showed a
lower proportion of patients with no problems in most
dimensions than those reported by the 3-level version
[15]—81.0% (226/279) versus 90.7% in mobility, 77.1%
(215/279) versus 85.2% in activity, 45.5% (127/279) versus
74.1% in pain or discomfort, and 48.0% (134/279) versus 77.8%
in anxiety or depression. The other 2 studies on the EQ-5D-3L
in asthma [16,17] did not report percentage distributions for
each dimension. This lower endorsement of the top response
option when compared with results from previous studies with
the EQ-5D-3L suggests that the “no problems” category (level
1 out of 3) is partially redistributed to the following intermediate
category, “slight” problems (level 2 out of 5), in the new 5-level
version. However, head-to-head studies are needed to ensure
that the new 5L version’s better properties we have observed,
compared with results from previous EQ-5D-3L studies [15,17],
are not explained by differences in patients’ characteristics or
design issues.
Studies that directly elicit preferences from representative
general population samples to derive value sets for the new
EQ-5D-5L, using a harmonized protocol, have already been
published for several countries [30,47-51], but they are not yet
developed in many others, including France. The EuroQol Group
developed the 3L-5L crosswalk value sets as a temporary
solution to estimate the EQ-5D-5L in such a situation [29]. The
difference between both indices in the negative extreme of the
theoretical range (–0.28 and –0.53) is explained by the method
used for the elicitation of the societal preference values to derive
the value set: time trade-off in the French general population
for the 3L version [52], and the composite method of time
trade-off with discrete choice experiments in the UK general
population for the new 5L version [23,30]. Our findings show
that the mean EQ-5D-5L indices obtained with both value sets
are quite similar (0.88 and 0.83), supporting that the 3L-5L
crosswalk is a good interim solution to calculate the EQ-5D-5L
index, until definitive EQ-5D-5L value sets are available.
The EQ-5D-5L index could discriminate among different known
groups in the hypothesized direction. In all the variables
evaluated, differences between extreme groups ranged from
0.07 to 0.2, therefore being equal to or higher than the minimal
important difference, previously estimated as 0.07 [31]. The
magnitude was moderate for differences among groups defined
by the presence of other chronic conditions and SABA use or
prescription and large for differences between patients with
well- and not well-controlled asthma measured with the ACQ.
McTaggart-Cowan et al [17], with the traditional EQ-5D-3L in
patients with asthma, also showed differences between extreme
groups >0.07, ranging from 0.07 to 0.18. It was not possible to
directly compare effect sizes with this study [17], as the
variables to define known groups were different. Mc
Taggart-Cowan et al reported a correlation of 0.37 for the ACQ
with the EQ-5D-3L index [17], similar to the 0.43 found in our
study with the EQ-5D-5L index. These findings indicate a good
construct validity for the EQ-5D-5L index, which, in general,
presented a greater discriminant capacity than the EQ-VAS
among the known groups evaluated.
Limitations and Strengths
Some potential limitations of this study need to be considered.
First, a direct comparison with the EQ-5D-3L was not possible.
Although previous EQ-5D-3L studies in asthma patients [15-17]
showed higher ceiling effects and lower discriminatory
properties than ours with the EQ-5D-5L, differences among
studies regarding patients’ and design characteristics cannot be
discarded. Second, as no asthma-specific HRQoL measure was
included in this study, we were unable to compare the generic
EQ-5D-5L with them. Studies evaluating the EQ-5D-3L in
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comparison to the Asthma Quality of Life Questionnaire [15-17]
or the Newcastle Asthma Symptoms Questionnaire [16] showed
that these disease-specific instruments were more sensitive to
change. Further head-to-head studies comparing the EQ-5D-5L
with disease-specific instruments are needed, mainly to compare
responsiveness. Third, the usability of online versus other
methods of survey administration could not be evaluated because
all patients completed the Web-based EQ-5D-5L. Fourth,
because the ASTRO-LAB project only included patients with
mild-to-moderate persistent asthma, the generalizability of our
results to those with intermittent or severe persistent asthma is
uncertain. The generalizability is also uncertain to patients older
than 40 years. Finally, it is important to note that 46.3%
(269/581) of participants in the ASTRO-LAB project did not
answer the Web-based survey. No differences in
sociodemographic characteristics, treatment, and comorbidity
were found between respondents and nonrespondents, and
differences detected in asthma control were minor. However,
there could be differences in other characteristics, which have
not been measured such as personality or other psychological
traits.
This study has several strengths that need to be highlighted.
First, embedding this study in an observational cohort in routine
care allowed us to select several appropriate known groups for
evaluating the EQ-5D-5L’s construct validity in patients with
asthma. The relationship between comorbid chronic conditions
and health is well established, and the associations of symptoms
control [53] with the HRQoL have been extensively studied in
this population. Furthermore, the ACQ, validated in 50
languages, is one of the most widely accepted instruments for
measuring asthma control [54].
Conclusions
In summary, our results provide support to the construct validity
of the EQ-5D-5L administered online to patients with asthma,
based on its discriminant ability for distinguishing among
health-related known groups, as well as its lower ceiling effect
than previously reported for the traditional 3-level version
[15,17]. The completion of the EQ-5D-5L by most of the
Web-based survey respondents supports the feasibility of this
administration form. As it was developed as a preference-based
health status measure, the EQ-5D-5L index allows combining
both length and quality of life, and calculates QALYs to measure
health outcomes in economic evaluations. All these findings
suggest that the new EQ-5D with 5 levels is a promising
instrument to compare the efficiency of different programs or
treatment strategies for asthma patients. Nevertheless, further
studies are recommended to evaluate the responsiveness over
time of the EQ-5D-5L among patients with asthma.
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